Media coverage about Neogen (NASDAQ:NEOG) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neogen earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.9949159036825 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- Neogen Co. (NEOG) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Can Neogen (NEOG) Stock Continue to Grow Earnings? (finance.yahoo.com)
- Stephens Reaffirms Hold Rating for Neogen (NEOG) (americanbankingnews.com)
- Reviewing Neogen (NEOG) and Cardiovascular Systems (CSII) (americanbankingnews.com)
- FY2019 EPS Estimates for Neogen Co. Boosted by William Blair (NEOG) (americanbankingnews.com)
NEOG has been the topic of a number of research analyst reports. Zacks Investment Research raised Neogen from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a report on Wednesday, October 11th. Stephens reaffirmed a “hold” rating and set a $62.00 target price on shares of Neogen in a report on Wednesday. Roth Capital set a $62.00 target price on Neogen and gave the stock a “hold” rating in a report on Thursday, January 4th. Finally, Craig Hallum increased their target price on Neogen from $46.50 to $60.00 and gave the stock a “hold” rating in a report on Thursday, December 7th. Five research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $63.25.
Neogen (NASDAQ:NEOG) last announced its quarterly earnings results on Wednesday, January 3rd. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.07. The business had revenue of $101.80 million for the quarter, compared to analysts’ expectations of $102.46 million. Neogen had a return on equity of 10.72% and a net margin of 13.47%. The business’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.29 EPS. research analysts expect that Neogen will post 1.04 EPS for the current year.
In related news, insider James L. Herbert sold 26,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $81.45, for a total value of $2,117,700.00. Following the sale, the insider now directly owns 879,430 shares in the company, valued at approximately $71,629,573.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Edward Bradley sold 17,824 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $80.32, for a total value of $1,431,623.68. Following the completion of the sale, the vice president now owns 27,212 shares in the company, valued at $2,185,667.84. The disclosure for this sale can be found here. Insiders have sold a total of 47,824 shares of company stock worth $3,870,364 over the last quarter. Insiders own 4.20% of the company’s stock.
Neogen Company Profile
Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.
What are top analysts saying about Neogen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neogen and related companies.